AAVR disruption as a producer-cell engineering strategy for enhanced supernatant-based recovery of selected AAV serotypes.
- DOI
- 10.1016/j.omta.2026.201830
- Published
- 2026 Sep 10
- Container
- Molecular therapy. Advances
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.omta.2026.201830,
title = {AAVR disruption as a producer-cell engineering strategy for enhanced supernatant-based recovery of selected AAV serotypes.},
author = {Sakamoto K and Yoshida K and Tsunekawa Y and Guzman Mendoza NA and Komaki Y and Onodera A and Okada T},
year = {2026},
journal = {Molecular therapy. Advances},
doi = {10.1016/j.omta.2026.201830},
url = {https://doi.org/10.1016/j.omta.2026.201830}
}RIS
TY - JOUR TI - AAVR disruption as a producer-cell engineering strategy for enhanced supernatant-based recovery of selected AAV serotypes. AU - Sakamoto K AU - Yoshida K AU - Tsunekawa Y AU - Guzman Mendoza NA AU - Komaki Y AU - Onodera A AU - Okada T PY - 2026 JO - Molecular therapy. Advances DO - 10.1016/j.omta.2026.201830 UR - https://doi.org/10.1016/j.omta.2026.201830 ER -
APA
K, S., K, Y., Y, T., NA, G. M., Y, K., A, O., & T, O. (2026). AAVR disruption as a producer-cell engineering strategy for enhanced supernatant-based recovery of selected AAV serotypes.. Molecular therapy. Advances. https://doi.org/10.1016/j.omta.2026.201830
Source records
- pubmed · retrieved 2026-09-26T13:09:56.445Z
- europe-pmc · retrieved 2026-09-26T13:09:56.437Z